Question: Which of the following, could not be a test for COVID-19-
a) PCR based test
b) Rapid Antigen tests
c) Antibody tests
d) Rorschach test
Answer: (d)
Related Facts:
- On 28 September, 2020 The World Health Organisation (WHO) made an announcement that it will provide about 120 million antigen rapid diagnostic tests in the months ahead.
- These tests will be available to low- and middle-income countries (LMIC).
- W.H.O has done milestone agreements for this purpose with the Abbott, SD Biosensor and the Gates Foundation.
- WHO Director General Tedros Adhanom Ghebreyesus has made following announcement regarding new rapid testing kits-
- This will enable the expansion of testing, particularly in hard-to-reach areas that do not have lab facilities or enough trained health workers to carry out PCR tests.
- The tests are priced at a maximum of $5 per unit, substantially cheaper than PCR tests.
- This also assured that there may be further coming down of testing costs.
- To achieve this purpose Volume guarantee agreements have been signed with rapid diagnostic test producers Abbott and SD Biosensor and the Bill and Melinda Gates Foundation (BMGF).
- WHO has declared that the tests provide reliable results in 15 to 30 minutes, as compared to a few hours or days, and at a lower price.
- This is a vital addition to their testing capacity and is especially important in areas of high transmission.
- It has been explained that the sooner Covid-19 is diagnosed, the quicker action can be taken to treat and isolate those with the virus and trace their contacts.
- Why these test preferred by WHO
- Portability
- The tests developed by Abbott and SD Biosensor are portable, reliable and easy to administer.
- According to the WHO through these kits, testing is possible in near-person, decentralized healthcare settings.
- apid Antigen Testing for SARS-CoV-2:-
- Rapid antigen tests are commonly used in the diagnosis of respiratory pathogens, including influenza viruses and respiratory syncytial virus (RSV).
- The US. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for antigen tests that can identify SARS-CoV-2.
- Antigen tests are immune assays that detect the presence of a specific viral antigen, which implies current viral infection.
- Antigen tests are currently authorized to be performed on nasopharyngeal or nasal swab specimens placed directly into the assay’s extraction buffer or reagent.
- The currently authorized antigen tests are not restricted to use on persons of a certain age.
- Antigen tests are relatively inexpensive and can be used at the point-of-care.
- The currently authorized devices return results in approximately 15 minutes.
- Antigen tests for SARS-CoV-2 are generally less sensitive than viral tests.
- Viral tests are highly sensitive and able to detect nucleic acid using reverse transcription polymerase chain reaction (RT-PCR).
Links:-
https://www.who.int/news-room/detail/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low–and-middle-income-countries
https://www.thehindubusinessline.com/news/world/who-to-offer-low-middle-income-nations-120-million-low-cost-rapid-antigen-tests-for-covid-19/article32721488.ece